BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 24499648)

  • 1. The effectiveness of dual-phase 18F-FDG PET/CT in the detection of epithelial ovarian carcinoma: a pilot study.
    Lee JK; Min KJ; So KA; Kim S; Hong JH
    J Ovarian Res; 2014 Feb; 7():15. PubMed ID: 24499648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of Clinical Molecular Typing of Breast Invasive Ductal Carcinoma Using
    Zhang J; Liu Y; Fan H; Wang W; Shao W; Cao G; Shi X
    Acad Radiol; 2023 Sep; 30 Suppl 2():S82-S92. PubMed ID: 36624021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of (18)F-FDG PET/CT in the preoperative evaluation of patients diagnosed with peritoneal carcinomatosis of ovarian origin, candidates to cytoreduction and hipec. A pending issue.
    Lopez-Lopez V; Cascales-Campos PA; Gil J; Frutos L; Andrade RJ; Fuster-Quiñonero M; Feliciangeli E; Gil E; Parrilla P
    Eur J Radiol; 2016 Oct; 85(10):1824-1828. PubMed ID: 27666623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Axillary Lymph Node Metastasis in Patients With Breast Cancer Using Dual-Phase FDG PET/CT.
    Sasada S; Masumoto N; Kimura Y; Kajitani K; Emi A; Kadoya T; Okada M
    AJR Am J Roentgenol; 2019 Nov; 213(5):1129-1135. PubMed ID: 31339353
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Liu S; Feng Z; Wen H; Jiang Z; Pan H; Deng Y; Zhang L; Ju X; Chen X; Wu X
    Jpn J Radiol; 2018 Sep; 36(9):544-550. PubMed ID: 29943313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical value of dual-time point 18F-FDG PET/CT for differentiating extrahepatic cholangiocarcinoma from benign disease.
    Choi EK; Yoo IeR; Kim SH; O JH; Choi WH; Na SJ; Park SY
    Clin Nucl Med; 2013 Mar; 38(3):e106-11. PubMed ID: 23354026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Vallius T; Peter A; Auranen A; Carpén O; Kemppainen J; Matomäki J; Oksa S; Roering P; Seppänen M; Grénman S; Hynninen J
    Gynecol Oncol; 2016 Jan; 140(1):29-35. PubMed ID: 26515076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of dual-time-point 18F-FDG PET/CT for identifying axillary lymph node metastasis in breast cancer patients.
    Choi WH; Yoo IR; O JH; Kim SH; Chung SK
    Br J Radiol; 2011 Jul; 84(1003):593-9. PubMed ID: 21081574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of standardized uptake value measurements of the primary lesions in proven cases of breast carcinoma with different degree of disease burden at diagnosis: does 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography predict tumor biology?
    Basu S; Mavi A; Cermik T; Houseni M; Alavi A
    Mol Imaging Biol; 2008; 10(1):62-6. PubMed ID: 18000713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative characterization of indeterminate large adrenal masses with dual tracer PET-CT using fluorine-18 fluorodeoxyglucose and gallium-68-DOTANOC: initial results.
    Naswa N; Sharma P; Soundararajan R; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
    Diagn Interv Radiol; 2013; 19(4):294-8. PubMed ID: 23439252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual time point FDG-PET/CT imaging... Potential tool for diagnosis of breast cancer.
    Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E
    Clin Radiol; 2008 Nov; 63(11):1213-27. PubMed ID: 18929039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of pulmonary lesions with low F-18 FDG uptake using double phase F-18 FDG PET/CT: comparison of visual and quantitative analyses.
    Kim IJ; Kim SJ; Kim YS; Lee TH; Jeong YJ
    Neoplasma; 2009; 56(1):33-9. PubMed ID: 19152243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG-PET/CT to predict optimal primary cytoreductive surgery in patients with advanced ovarian cancer: preliminary results.
    Alessi A; Martinelli F; Padovano B; Serafini G; Lorusso D; Lorenzoni A; Ditto A; Lecce F; Mira M; Donfrancesco C; Raspagliesi F; Crippa F
    Tumori; 2016; 102(1):103-7. PubMed ID: 26350201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of nodal metastases by 18F-FDG PET/CT in apparent early stage ovarian cancer: a prospective study.
    Signorelli M; Guerra L; Pirovano C; Crivellaro C; Fruscio R; Buda A; Cuzzucrea M; Elisei F; Ceppi L; Messa C
    Gynecol Oncol; 2013 Nov; 131(2):395-9. PubMed ID: 23988414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Peritoneal carcinomatosis from ovarian cancer: role of 18F-FDG-PET/CT and CA125].
    Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Stabile Ianora AA; Giganti M; Niccoli Asabella A
    Recenti Prog Med; 2012 Nov; 103(11):510-4. PubMed ID: 23096741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revisiting the clinical value of 18F-FDG PET/CT in detection of recurrent epithelial ovarian carcinomas: correlation with histology, serum CA-125 assay, and conventional radiological modalities.
    Antunovic L; Cimitan M; Borsatti E; Baresic T; Sorio R; Giorda G; Steffan A; Balestreri L; Tatta R; Pepe G; Rubello D; Cecchin D; Canzonieri V
    Clin Nucl Med; 2012 Aug; 37(8):e184-8. PubMed ID: 22785525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels.
    Palomar A; Nanni C; Castellucci P; Ambrosini V; Montini GC; Allegri V; Pettinato C; Al-Nahhas A; Soriano A; Grassetto G; Rubello D; Fanti S
    Mol Imaging Biol; 2012 Feb; 14(1):123-9. PubMed ID: 21240639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of (18)F-FDG PET/CT in the Detection of Ovarian Malignancy.
    Park T; Lee S; Park S; Lee E; Pahk K; Rhee S; Cho J; Kim C; Eo JS; Choe JG; Kim S
    Nucl Med Mol Imaging; 2015 Mar; 49(1):42-51. PubMed ID: 25774237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.